全文获取类型
收费全文 | 540篇 |
免费 | 48篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 9篇 |
妇产科学 | 18篇 |
基础医学 | 34篇 |
口腔科学 | 14篇 |
临床医学 | 49篇 |
内科学 | 202篇 |
皮肤病学 | 4篇 |
神经病学 | 6篇 |
特种医学 | 61篇 |
外科学 | 20篇 |
综合类 | 11篇 |
预防医学 | 9篇 |
眼科学 | 3篇 |
药学 | 9篇 |
中国医学 | 3篇 |
肿瘤学 | 133篇 |
出版年
2022年 | 4篇 |
2021年 | 10篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 9篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 11篇 |
2014年 | 15篇 |
2013年 | 14篇 |
2012年 | 22篇 |
2011年 | 21篇 |
2010年 | 10篇 |
2009年 | 9篇 |
2008年 | 18篇 |
2007年 | 28篇 |
2006年 | 29篇 |
2005年 | 21篇 |
2004年 | 26篇 |
2003年 | 27篇 |
2002年 | 19篇 |
2001年 | 19篇 |
2000年 | 14篇 |
1999年 | 28篇 |
1998年 | 23篇 |
1997年 | 13篇 |
1996年 | 13篇 |
1995年 | 15篇 |
1994年 | 9篇 |
1993年 | 17篇 |
1992年 | 7篇 |
1991年 | 11篇 |
1990年 | 4篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1982年 | 4篇 |
1980年 | 7篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1959年 | 2篇 |
1958年 | 2篇 |
1957年 | 6篇 |
1956年 | 4篇 |
1955年 | 4篇 |
1954年 | 5篇 |
1950年 | 2篇 |
排序方式: 共有589条查询结果,搜索用时 10 毫秒
61.
Simpson L Ansell SM Colgan JP Habermann TM Inwards DJ Ristow KM Johnston PB Markovic SN Micallef IN Porrata LF Witzig TE 《Leukemia & lymphoma》2007,48(7):1332-1337
DHAP (dexamethasone, cytosine arabinoside and cis-platinum) is a commonly used regimen for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The optimal treatment for patients who do not respond to DHAP, but are still potential candidates for autologous stem cell transplantation, is unclear. One option is to proceed with an alternative chemotherapy regimen such as ifosfamide, carboplatin, and etoposide (ICE). The overall response rate (ORR) and overall survival (OS) associated with this chemotherapy sequence is unknown. Patients with DLBCL receiving DHAP as the first salvage therapy without response followed by ICE as second salvage were studied to learn the ORR to ICE and OS. The ORR to ICE in these DHAP-failures was 52% (11/21) with 14% (3/21) complete responses and 38% (8/21) partial responses. Nine patients (43%) were able to proceed to transplant and 29% (6/21) are long-term survivors. In patients with stable disease after DHAP the ORR was 67% (8/12) with 42% (5/12) becoming long-term survivors. In contrast, only 33% (3/9) of patients who had progressive disease on DHAP responded to ICE with only one patient achieving a durable response. Patients with stable disease after DHAP can be salvaged with ICE-based chemotherapy regimens whereas patients who progress on DHAP have a poor outcome. Patients with progressive disease on DHAP should be considered for alternative salvage regimens or experimental therapy. 相似文献
62.
63.
MSTM Almeida SCB Lima LL Carvalho JVM Almeida LG Santos JRA Rolim TE Rocha 《Journal of cutaneous pathology》2010,37(11):1170-1173
Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by small vessel involvement that leads to tissue ischemia and fibroblast stimulation resulting in accumulation of collagen (fibrosis) in the skin and internal organs. Lipomembranous panniculitis is a peculiar type of fat necrosis and has been reported with clinical conditions, commonly with peripheral vascular diseases. We describe a case of a 43‐year‐old woman with SSc manifestations, who presented with black scaly skin plaques, associated with thickening of the subcutaneous fat tissue, on the lateral surface of her thighs, her calves, gluteal area and lower abdomen. Biopsy revealed lipomembranous panniculitis. Lipomembranous changes have been seen in connective tissue disorders such as lupus profundus, morphea, systemic sclerosis and panniculitis associated with dermatomyositis, but rarely in thighs, calves, gluteal area and lower abdomen. Almeida MSTM, Lima SCB, Carvalho LL, Almeida JVM, Santos LG, Rolim JRA, Rocha TE. Panniculitis–An unusual cutaneous manifestation of systemic sclerosis. 相似文献
64.
Hysterosalpingography was performed in 31 patients by means of a low-dose scanning-beam digital radiographic system. The technique permits adequate evaluation of gynecologic abnormalities while allowing significant reduction in radiation: 2.4-mR (6.1 X 10(-7) C/kg) exposure to the skin and 0.7-mrad (7 X 10(-6) Gy) mean dose to the ovaries per image obtained. Sixteen patients demonstrated readily recognizable and documented abnormalities, corroborated by laparoscopy, laparotomy, or other supportive evidence. 相似文献
65.
Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma 下载免费PDF全文
Thomas E. Witzig Pier Luigi Zinzani Thomas M. Habermann Joseph M. Tuscano Johannes Drach Radhakrishnan Ramchandren Sevgi Kalayoglu Besisik Kenichi Takeshita Marie‐Laure Casadebaig Bravo Lei Zhang Tommy Fu Andre Goy 《American journal of hematology》2017,92(10):E575-E583
Mantle cell lymphoma (MCL) is a type of non‐Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post‐bortezomib). The purpose of this report is to provide longer follow‐up on the MCL‐001 study (follow‐ups were 6.8 [NHL‐002], 7.6 [NHL‐003], and 52.2 [MCL‐001] months). The 206 relapsed MCL patients treated with single‐agent lenalidomide (25 mg/day PO, days 1 to 21 every 28‐days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow‐up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%‐29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single‐agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib. 相似文献
66.
67.
GABRIEL O. TE MD MARGARET J. HAMILTON MA FRANKLIN M. RIZER MD KIMBERLY A. SCHATZ MA PETER N. ARKIS MA HEATHER C. ROSE MA Made possible by a grant from the Warren Hearing Research Foundation. 《Otolaryngology--head and neck surgery》1996,115(6):508-512
A number of studies have demonstrated that cochlear implants provide an improved auditory signal and enhance the development of speech-perception and production skills for profoundly deaf children. However, exactly when these early speech skills begin to develop remains unclear. To explore this issue, we observed, for a 1-year period, four prelingually deaf children who underwent implantation consecutively within 1 month of each other, and we paid particular attention to the first few months of rehabilitation. We found immediate speech scores as early as the first day of implant tune-up. Speech production continued to improve rapidly throughout the first 4 months but exhibited a generally slower rate of progress in some of the speech-production skills at 1 year. We also found vowel-production skills to be the easiest to achieve, with word-pattern recognition and consonant voicing of intermediate difficulty. Consonant placing and manner of consonant production were the hardest skills to achieve. Results of speech-perception tests 1 year after implantation were markedly improved over preimplantation levels in three of the four children. These early speech changes stress the need for maximization of the capability of the cochlear implant by institution of immediate and intensive speech rehabilitation efforts for prelingually deaf children. (Otolaryngol Head Neck Surg 1996;115:508-12.) 相似文献
68.
PJ Smith ; TE Miller ; J Fraser ; JW Smith ; JR Svirbely ; S Rudmann ; PL Strohm ; M Kennedy 《Transfusion》1991,31(4):313-317
Four empirical studies were conducted for better understanding of the nature of problem-solving activities by medical technologists and medical technology students when performing antibody identification tasks. The results indicated the importance of strategies that ensure the collection of converging evidence, as these strategies protect against the fallibility of commonly used heuristics and against errors due to simple slips. The results also indicate that not only do students make significant numbers of errors, but so do practicing technologists. In one of the studies covering a 1-year period, for instance, a group of 16 technologists made a total of 41 errors in 1057 cases. On the basis of these findings, several alternatives are proposed to reduce errors. 相似文献
69.
Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood 总被引:7,自引:4,他引:7
Wada M; Bartram CR; Nakamura H; Hachiya M; Chen DL; Borenstein J; Miller CW; Ludwig L; Hansen-Hagge TE; Ludwig WD 《Blood》1993,82(10):3163-3169
p53 mutations are found in a wide variety of cancers, including hematologic malignancies. These alterations apparently contribute to development of the malignant phenotype. We analyzed a large series of lymphoid (330 cases) and a smaller series of myeloid (29 cases) malignancies of childhood for p53 mutations by single-strand conformational polymorphism (SSCP) following polymerase chain reaction. Samples with abnormal SSCP were reamplified and analyzed by direct sequencing method. p53 mutations were detected within the known mutational hotspots (exons 5 to 8) in 8 of 330 lymphoid malignancies, and in none of 29 myeloid malignancies, showing that the frequency of p53 mutations in childhood lymphoid malignancies was very low (8 of 330 cases [2%]). Four of these patients had very aggressive, fatal acute lymphocytic leukemia (ALL). None of 13 infants and none of 48 patients with T-lineage leukemia had detectable p53 mutations in their ALL cells. Exceptionally, p53 mutations were comparatively frequent in a small sample of B-cell non-Hodgkin's lymphomas (2 of 8 cases). Mutations were detected in samples from two patients with ALL at relapse; these were not detected in samples at initial diagnosis from the same patients, suggesting that p53 mutations may be associated with progression to a more malignant phenotype. Seven of eight alterations of p53 were missense mutations, and seven of eight samples may be heterozygous for the mutant p53, indicating that p53 protein may act in a dominant negative fashion. 相似文献
70.
Jonas?Paludo Jithma?P.?Abeykoon Amanda?Shreders Stephen?M.?Ansell Shaji?Kumar Sikander?Ailawadhi Rebecca?L.?King Amber?B.?Koehler Craig?B.?Reeder Francis?K.?Buadi Angela?Dispenzieri Martha?Q.?Lacy David?Dingli Thomas?E.?Witzig Ronald?S.?Go Wilson?I.?Gonsalves Taxiarchis?Kourelis Rahma?Warsame Nelson?Leung Thomas?M.?Habermann Suzanne?Hayman Yi?Lin Robert?A.?Kyle S.?Vincent?Rajkumar Morie?A.?Gertz Prashant?KapoorEmail author 《Annals of hematology》2018,97(8):1417-1425
The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients’ MYD88L265P mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM). In the treatment-naïve setting, overall response rate (ORR) was 93% with BR versus 96% with DRC (p?=?0.55). Two-year progression-free survival (PFS) with BR and DRC was 88 and 61%, respectively (p?=?0.07). In salvage setting, ORR was 95% with BR versus 87% with DRC, p?=?0.45; median PFS with BR was 58 versus 32 months with DRC (2-year PFS was 66 versus 53%; p?=?0.08). Median disease-specific survival was not reached with BR versus 166 months with DRC (p?=?0.51). The time-to-event endpoints and depth of response were independent of the MYD88 mutation status. Grade ≥?3 adverse events of both regimens were comparable. A trend for longer PFS was observed with BR although the regimens have comparable toxicities. The activity of BR and DRC appears to be unaffected by patients’ MYD88 mutation status. 相似文献